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1. Introduction 
Neuromuscular disorders include a variety of conditions that affect motor neurons (spinal 
muscular atrophy), peripheral nerves (neuropathy), neuromuscular junction (myasthenia 
gravis) or muscle fibers (myopathy) (1). 
Myopathy is characterized by primary and generally irreversible skeletal muscle tissue 
degeneration, including genetic, inflammatory, metabolic or endocrine disorders and the 
different are charaterized by the muscle fibre type affected, mode of inheritance, age of 
onset and course of evolution (2,3,4). 
The term muscular dystrophy has been used in cases of rapidly progressive myopathy as 
well as of slow progressive degeneration of muscle, such as myotonic dystrophy (2). 
Myotonic Dystrophy (MD) is defined as the most common inherited myopathy in adults, 
with multisystemic involvement (cardiovascular, respiratory, nervous, visual, endocrine), 
autossomal dominant pattern and distinct clinical manifestations (2,5,6). Depending on the 
genetic trait, MD is classified as type 1 (MD-1), type 2 (MD-2) (7), or type 3 (8); being the 
type 1 the most common and the type 3, very rare. 
The MD-1, described by Steinert in 1909, is caused by expansion of CTG nucleotides repeat 
in the region of the gene for dystrophy myotonic protein kinase (DMPK) on chromosome 19; 
over 35 and ranging from 80 to more than 4,000 repetitions in the affected individuals. This 
abnormal protein is responsible for the disability of muscle, cardiac and nervous cells, 
involving several systems (9). 
This disease can be classified in: congenital, infantile, classic (age of onset between 10 to 50 
years) and with minimal involvement (10). Usually the earlier the onset of symptoms, the 
greater the number of repetitions of the nucleotides (7,11). 
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The muscle involvement is the main clinical feature with variations in the degree of 
weakness (facial, neck and distal muscles of limbs), as well as myotonia. In the congenital 
form, the deficit is prominent at birth without myotonia. In the infantile form, weakness is 
relatively mild, and in adults form there is slowly progression of the symptoms (11). 
In contrast to muscular dystrophy, the congenital myopathy is described as non-progressive 
or slowly progressive and rarely fatal disease. Among them is included the Congenital Fibre 
Type Disproportion (CFTD) (12). The CFTD is a congenital myopathy described by Brooke 
(13) as having generalized weakness, hypotonia at birth and slow progression of symptoms 
associated with abnormal histological predominance of type 1 muscle fibres, and smaller 
size of at least 12% than type 2. The patients have abnormalities such as congenital hip 
dislocation, foot deformities, kyphoscoliosis, ligament laxity, high palate and underweight 
(14,15,16,17). 
The CFTD pattern suggests a autossomal dominant trait although sporadic recessive cases 
has been described (18,19,20,21). Distinct mutations in the gene that codes the α-skeletal 
muscle actin (ACTA1), selenoprotein N (SEPN1) and α-tropomyosin (TPM3) proteins were 
identified in some cases, but the molecular mechanisms that cause the disparity of the fibres 
are still unknown (22,23). 
Individuals with CFTD show different degrees of weakness, more severe in the early stages 
of development, especially in the lower limbs (20). Generally they have a good prognosis, 
but in some cases they may be associated with respiratory (14,20) or cardiac (16,21) failures.  
Considering the CFTD and MD-1, both have weakness as the main physical limitation 
(17,24,25) and the individuals become more and more dependent to achieve their routine 
activities. Rehabilitation programs must measure and maximize patients motor skills and 
optimizing their functionality.  
 Now a days, several therapeutic techniques and other health professionals assessment tools 
can be used for patient selection, therapeutic monitoring and to establish prognosis for 
recovery (26).  
 Generally, the evaluations are qualitative test, not allowing for the individual assessment of 
the recovery of the better patients (27). Currently, Medical Research Council scale (MRC) for 
measuring muscle strength is being used for clinical examination and patient follow-up  
however, it does not reflect the real abilities of each individual (28)There are several scales to 
measure function in neuromuscular diseases, including the Barthel Index (BI), Vignos scale 
and Motor Function Measure (MFM) (28). 
The MFM have been developed and validated for neuromuscular diseases by the research 
group of the Department of Pediatric Reeducation L'Escale, Lyon, France.This is a more 
comprehensive, specific and functional scale, analyzing the function of the head, trunk, 
proximal and distal segments in several neuromuscular diseases (28). 
The scale comprises 32 items, including static and dynamic evaluations, divided into three 
dimensions: 
- Dimension 1 (D1): a standing position and transfers, with 13 items 
- Dimension 2 (D2): axial and proximal motor function, with 12 items. 
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- Dimension 3 (D3): distal motor function, with seven items, six of which are related to 
the upper limbs. 
Each item is graduated on a 4-point scale (scores 0 to 3), with the instructions detailed in the 
scoring manual, specific to each item. Score 0 - can not start the requested task or can not 
keep the starting position. Score 1 – initializes the item. Score 2 - partially performs the 
requested movement or fully realized, but imperfectly. Score 3 - completes the item, with 
controlled movement (normal).  
In cases of tendon retraction or joint limitation, the individual is graduated as not presenting 
adequate strength to perform the movement, preventing them from receiving the maximum 
degree. The total score and each dimension are expressed in percentages relative to 
maximum score (96 points).  
In 2008, Iwabe et al. (29) demonstrated the reliability of the Portuguese version’s MFM (P-
MFM), showing a high correlation intra and inter examiner results. 
The aim of this chapter is to describe the validation of the P-MFM and its applicability to 
evaluate the motor function in muscular myopathy and dystrophy individuals. 
2. P-MFM Validation 
The population comprised a total of 65 patients, 37 male and 28 female, average 33.09 years 
(8-60 years), with laboratory findings confirming clinical diagnosis of congenital muscular 
dystrophy (n = 7), Duchenne (n = 5), Becker (n = 4), limb girdle (n = 4), facioscapulohumeral 
(n = 8), distal myopathy (n = 4), mitochondrial (n = 3), centrocore (n = 6), congenital fibre 
types disproportion (n = 1), myotonic dystrophy (n = 21) and spinal muscular atrophy (n = 
2); outcome in the Neuromuscular Diseases Clinic of the Faculty of Medical Sciences, 
Campinas State University (UNICAMP). 
Patients were evaluated according to the P-MFM, BI and Vignos scales. All evaluations were 
performed by the same examiner and BI questions were answered by the patient, or in some 
cases with the help of their parents. 
Statistical analysis - the total scores and each of the three dimensions of P-MFM were 
correlated with Vignos scale and BI by the Spearman correlation coefficient, with 
significance level of 5% (p <0.05). 
It was observed that in P-MFM scale, both its three dimensions and total score, were 
correlated negatively and significantly with the Vignos scale, and correlated positively and 
significantly with the BI (Table 1). 
 
P-MFM Vignos scale BI 
Dimension 1 -0,858* 0,946* 
Dimension 2 -0,852* 0,871* 
Dimension 3 -0,671* 0,736* 
Total -0,894* 0,980* 
* - p < 0,001 
Table 1. Correlation between P-MFM, Vignos scale and BI. 
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Validation is defined as the ability of an instrument to measure a particular aspect, and for 
this it is necessary the correlation with other validate scales, and similar characteristics (30). 
Miller et al. (31) defined some factors for the scale’s development and validation. The 
instrument must represent the function at the moment, following the patient’s evolution 
over the time, and each individual serving as his own control. 
The MFM was developed for this purpose, containing items easily implementable and 
understandable by patients from different age groups (6-60 years). This scale has the 
capacity of analyze the most important motor functions and deficiency in several 
neuromuscular diseases. It can measure the activity of the proximal and distal segments 
members; as well as the standing position and transfering at the moment and over time 
(28). 
The capacity of MFM scale to analyze the various body segments and their mobility in all 
neuromuscular diseases, empathizes its use in research and clinical. To be applied in Brazil, 
it was necessary perform the validation process of the Portuguese version, considering that 
the scale item was approved in reproducibility and reliability (29). 
In Brazil, there are only two assessment instruments validated for patients with dystrophy 
(32).  
The P-MFM validation study used two functional scales, the BI and Vignos scale 
(33,34,35,36). BI and Vignos scale are clinical instruments often used to assess the level of 
functionality in neuromuscular diseases (35). These two scales were used in the study by 
Nair et al. (37), with Duchenne muscular dystrophy, showing to be a valid instrument for 
assessing the functional limitations in this patients. 
Previous validation studies about functional neuromuscular diseases using the BI and 
Vignos scale (28,38,39) demonstrated the correlation between them. Studies analyzing the 
functionality of individuals with neuromuscular diseases after clinical or surgical treatment, 
or correlating it to other parameters, such as muscle strength using these same scales 
(40,41,42,43,44) established them as easy to use instruments. 
In this study, we found a high significant correlation among the P-MFM, Vignos scale and 
BI, allowing for validation of the Portuguese version of MFM. 
3. Applicability of P-MFM in family with CFTD, associated muscle magnetic 
ressonance 
We studied members of a family with clinical and laboratory CFTD. They were evaluated 
for muscle strength (MRC scale) and motor function by the scale P-MFM (29) and were 
previously examined in the Neuromuscular Diseases Clinic through physical examination, 
serological and neurophysiological tests and muscle biopsy. One sample was taken from the 
biceps muscle from the father in a family. The obtained sample was fixed in isopentane and 
frozen in liquid nitrogen. Sections were stained with hematoxylin-eosin (H & E), Gomori 
trichrome modified (TRI) or oil red O and analyzed by histochemical techniques for 
nicotinamide adenine dinucleotide phosphatase, nicotinamide dehydrogenase tetrazolium 
reductase (NADH-TR), succinate dehydrogenase (SDH) and immunohistochemistry for 
slow and fast myosin, desmin and alpha B crystalline. 
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Muscle magnetic resonance imaging (mMRI) was performed in magnetic field of 2.0 Tesla, 
T1-weighted images in axial plane for the leg muscles from each patient, according to De 
Cauwer et al. (45).  
Image data were analyzed quantitatively according to the degree proposed by Mercuri et al. 
(46) and modified by Nucci (47). 
0 = normal appearance 
1 = slight appearance of "moth-food", with sporadic areas of hyperintensity. 
2 = moderate appearance of "moth-food" with related areas of hyperintense spaced, 
comprising less than 30% of muscle volume. 
= 2.5 appearance of "moth-food" with moderate hyper spaced areas, comprising 30 to 60% of 
muscle volume. 
3 = severe appearance of "moth-food", with numerous areas of confluence of hyperintense 
with muscle still present in the periphery. 
4 = complete fatty degeneration, with replacement of muscle by connective tissue and fat. 
The family pedigree is shown in Figure 1. It was not possible to examine patient´s mother (I-
1) and patient´s uncle (I-2). Throughout the family´s history, the patient´s mother was 
indicated as asymptomatic, and the uncle as having the phenotype very similar with 
myopathy aspects.. Thus, I-2 was marked as affected in the pedigree. 
 
 
Fig. 1. Family pedigree. The grey figures are the affects cases. The white figures are the 
normal cases  
5 3 1 
2 
2 4 
1 3 4 
1 2 
 I 
II 
III 
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CASE II -2 Male, 48-year-old with consanguineous parents, complaining about muscle 
weakness since childhood, considered a "sick child" due to limitations in physical activities 
and difficulty in gaining weight. The acquisition of motor milestones was delayed, just 
being able to walk around 5 years old. The initial clinical examination showed a 
collaborative and lanky patient (1.78 meters, 48 kg), with severe scoliosis dextro-convex 
compensate cervical, and high palate. A complex gait was observed due to the misalignment 
of the spinal cord and the tendency to walk with his feet fallen. The muscles stretch reflexes 
were hypoactive, but the cranial nerves, the cognition and sensibility were normal. The 
laboratory findings for creatine kinase (CK) showed 181 U / L (normal values below 170), 
and the study for motor and sensory nerves conduction were within normal limits. 
Electromyography (EMG) of the deltoid and biceps brachii showed the most potential of 
motor units with respect polyphasic, low amplitude and short duration, myopathy 
indicative,, despite the present right quadriceps were relatively normal. The 
electrocardiogram (ECG) and routine laboratory tests showed no abnormalities. The main 
morphologic abnormality in biopsy was a disproportion of the fibre types with small type 1  
  
 
Fig. 2. a - H & E staining showing two populations of muscle fibres with different diameters 
average. b - NADH-TR staining where small diameter fibres show a higher oxidative 
activity (type 1) than the large fibres (type 2). c - Immunohistochemistry for myosin slow - 
small diameter fibres are positively stained for slow myosin fibres (type 1), in contrast to the 
larger fibres that are unmarked (type 2). 
a b 
c 
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fibres (Figures 10 a-c). The electron microscopy showed neither central focus, minifocus, 
nemaline bodies nor mitochondrial alterations, also no protein deposits were observed. 
The most significant data from the biceps muscle biopsy from case II-2 is illustrated in figure 
2 c.  
CASE III - 1 Female, 13 years old, daughter of the Case II-2, non-consanguineous parents. 
She was born at 40 weeks gestational age, 50 cm height, 2.670g weight, cesarean delivery for 
fetal distress, and a history of reduced fetal movements. The child presented a congenital 
hypotonia and delayed motor development, acquiring the standing posture approximately 
at 19 months of age with a clumsy posture. She did not gain weight like a normal child and 
physical activities were restricted. Like her father, she showed progressive deviation of the 
spine, and recently complained with pain in the dorsal region, especially during physical 
activity. On examination, the patient was a tall and thin child, with marked kyphoscoliosis, 
long face, high palate, atrophy muscle and global hypoactive muscle stretch reflexes. There 
were no motor deficits in the face or external ophthalmoparesis. CK values were between 65 
to 73 U / L (normal below 145 U / L). Glucose, IgA, IgG and IgM, transaminases, and 
electrolytes were normal, but with a TSH value of 7.23 IU / ml ( normal 4.5) and FT4 of 1.68 
ng / dl (normal range). Sensory nerve conduction velocity (median, ulnar, radial and sural) 
and motor nerves (median, ulnar, peroneal and tibial) were within normal limits. EMG of 
deltoid, biceps, rectus femoris, tibialis anterior and gastrocnemius showed myopathic 
changes. The patient was doing physical therapy in 50-minute sessions per week in pediatric 
neurology ambulatory UNICAMP. At 15 years old she had an episode of severe pneumonia 
which complicated by fatal septicemia. 
CASE III - 3. Male, 10 years old, third son of the case II -2. He was born at 38 weeks 
gestational age with cesarean delivery, and had a history of reduced fetal movements. The 
child presented a congenital hypotonia and delayed motor development to roll, sit and 
crawl, acquiring the standing posture around 11 months age, and unsteady gait around 2 
years old. According to his parents, he used to present recurrent episodes of urinary tract 
infection, pneumonia and ear infections during childhood. In the first consultation, there 
was a decreased in motor performance, diffused muscle hypotrophy, scoliosis, high palate 
and hypoactivity of muscle stretch reflexes. There was no facial weakness or external 
ophthalmoparesis. Sensibility and cognition were preserved. Values of CK, glucose, IgA, 
IgG and IgM, transaminases, electrolytes, vitamin B12 and TSH were normal. The EMG test 
was not performed at the request of his father. 
CASE III - 5. Male, 9 months of age, born after 38 weeks of pregnancy, cesarean delivery, 
and with a history of reduced fetal movements. He had a slight delay in motor 
development, and at clinical examination an evident hypotonia, with preserved muscle 
stretch reflexes. Laboratory findings revealed mild microcytic hypochromic anemia, CK of 
89 U / L (normal 170 U / L) and TSH and T4 L-us normal. Clinical monitoring was 
suggested by over time. He was re-evaluated at 2 years and 6 months of age. At this time he 
was walking without support, with mild myopathic patterns. The muscle stretch reflexes 
were hypoactive, hypotonia clearly present and dextro-convex scoliosis and lumbar cord. 
For treatment physiotherapy was indicated. We did not evaluate him using the scale P-MFM 
due to this method is recommended for patients over 6 years. 
Figure 3 a-c illustrate the data from the mMRI for cases II-2, III-1 and III3. 
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Fig. 3.a - Case II-2. mMRI, T1-weighted images and axial sections showing fatty infiltration 
of muscle compartments of the anterior, posterior deep and superficial leg, with greater 
involvement of the anterior and deep posterior compartment.  
 
Fig. 3.b - Case III-1. mMRI, T1-weighted images and axial sections showing fatty infiltration 
of muscle compartments of the anterior, posterior deep and superficial leg with less 
alteration of the superficial posterior compartment. Note the symmetry condition.  
Figure 4 represents the scores of each dimension and the total score of P-MFM in cases II - 2, 
III - 1 and III - 3, at different ages. 
Different types of muscle fibres are present in the muscles of normal adults in a typical 
mosaic pattern, with ratio of approximately 1 / 3 of fibre type 1 (Figures 2a and 2b). The 
differentiation of the fibres occurs between the 22° week of gestation and the first year of 
life. At birth, the child had about 40% of type 1 fibre. The percentage of these fibres 
increased up to 60% in the first year of life and remained unchanged until adulthood. The 
sizes of type 1 and 2 fibres are almost equal in childhood, with little variability in relation to 
adults (75). 
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Fig. 3.c - Case III-3. mMRI, T1-weighted images and axial sections showing fatty infiltration 
of muscle compartments of the anterior, posterior deep and superficial leg with less 
alteration of the superficial posterior compartment. Note the relative preservation of muscle 
compared with the previous cases. 
 
Fig. 4. Distribution of scores for each dimension and total score of the P-MFM from each 
patient. The evaluation at 10 and 12 years refers to case III-3, the evaluation at 13 years refers 
to the case III-1, and evaluation at 48 and 49 years to case II-2.  
Age (years)
Total score 
MFM-P 
D1 standing position and transfers (%) 
 
D2 proximal and axial motor function (%) 
 
 
D3 distal motor function (%) 
 
TOTAL SCORE (%) 
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The mutation in the genes ACTA1 (22), SEPN1 (48) or TPM3 (23) express the morphological 
and histochemical alteration in CFTD (49). Since the first description of this disease, 
approximately 67 cases have been described (16), but just a few cases originally in Brazil 
(50).  
Clinical characteristics of patients in the study were similar to those described in previously 
works, such as congenital hypotonia, delayed motor skills, kyphoscoliosis and high palate. 
Also data for additional tests as EMG myopathic pattern and CK levels are normal or 
slightly altered according to the literature (14,17,51,52,53,54). 
The natural course of CFTD is in most cases characterized by slow progression of weakness, 
affecting mainly the lower limbs beginning at the proximal muscles and progressing to 
distal. However, in some patients weakness is widespread (16,17). The deterioration of 
muscle strength was observed in our patients, with difficulties to standing, walking and 
running. During assessment of motor function, all patients showed greater difficulties in 
activities related to standing position and transfers (Dimension 1) due to loss of muscle 
strength.  
All the seven cases described by Sobrado et al. (17) had difficulty in activities like those 
described in our study (raising themselves from a chair or from the floor, walking or 
running on heels), in addition to muscle weakness in lower limbs (grade 3 to 4). These data 
agree with descriptions of Linssen et al. (55) in which cases presenting degree of muscle 
strength equal to 4, have functional limitations. 
Some patients with CFTD have severe respiratory complications, as with the patient in the 
case III - 1. This condition could happen due to hypotrophy of type 1 fibres found in the 
respiratory muscles, including the diaphragm (14,16,20,22,48,49) or as a result of severe 
kyphoscoliosis, which progressively diminished lung capacity. Thus, it is important that 
patients be monitored for maintenance of a postural alignment and breathing function.  
The mMRI is proposed as a useful method to study congenital and metabolic myopathy 
(56), although there are few publications using this technique in CFTD (17). In the current 
study, it was possible to qualitatively observe intense changes in distal segments of the 
lower limbs in all images of affected patients. These changes correspond to an increased leg 
muscle weakness with difficulties in performing activities according to the P-MFM scale. 
The evaluation of muscle function by P-MFM associated with the examination of mMRI led 
to a full characterization and motor phenotype evaluation in these patients. The first 
evaluation using the P-MFM in family’s members showed a co-occurrence of more intense 
abnormalities in the mMRI with the worst scores in standing position and transfer. There 
was also a correlation between the age and severity of the mMRI and P-MFM score. 
4. Correlation between muscle strength and P-MFM in myotonic dystrophy  
The study included a total of 21 patients, 10 males and 11 females, from 20 to 60 years old, 
with an average of 38.14 years, and with clinical-laboratory diagnosis of MD-1, outcoming 
the Neuromuscular Diseases Clinic Clinical Hospital of UNICAMP.  
Patients were evaluated by MFM-P (29) and submitted to examination of muscle strength by 
MRC scale (1976) that includes 14 muscle groups of upper limbs (UL), 14 groups in the 
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cervical muscles and lower limbs, trunk flexors and extensors. Muscles were grouped 
according to the segment’s function. 
Statistical analysis - The correlation of each of the three dimensions and the total score P-
MFM, with the degrees obtained by the MRC scale in the muscle groups studied was made 
using Pearson's correlation coefficient. 
Patients showed a variation in the degree of muscle strength from 2 to 4. In the distal muscle 
groups, such as flexors, extensors of the fingers and wrist extensors, the degrees of force 
were grade 2-4. And the proximal muscles strength varied from 3 to 4. 
In the lower limbs, muscle strength ranged from grade 2 to 5. In distal muscles the strength 
varied from 2 to 4 and the proximal muscles strength ranged from grade 3 to 5. Also the 
evaluation of axial muscles showed strength ranged varying from grade 2 to 4.  
The deficits found in patients were symmetrical in both the axial region and in the upper 
and lower segments.  
To analyze the distribution of the total score and each dimension of the P-MFM scale values 
were arbitrarily classified as: mild (100 to 70%, independent patient), moderate (69.9 to 50%, 
partially dependent) and severe (<50%, dependent). 
A higher number of patients presented lower scores (<50%) in activities related to P-MFM 
Dimension 1 (standing position and transfers) (Table 2). 
 
Score Dimension (score) 
D1 D2 D3 Total score 
Mild 
(100– 70%) 
4 
(89,74 – 76,92) 
18 
(100 – 80,56) 
20 
(100 – 71,43) 
12 
(95,83 – 72,92) 
Moderate 
(69,9– 50%) 
7 
(69,23 – 53,85) 
3 
(63,89 – 58,33) 
01 
(57,14) 
09 
(66,67 – 54,17) 
Severe 
(< 50%) 
10 
(48,72 – 25-64) 
---- --- --- 
Table 2. Number of patients according to scores obtained in each dimension and total score 
of P-MFM 
Analyzing the correlations between the degrees of upper limb strength in each dimension 
and total score P-MFM, we observed a significantly positive correlation between the 
proximal muscles and Dimension1 and Dimension 2, and correlation between the distal 
muscles and Dimension 3.  
Similarly for lower limbs, we observed a significantly positive correlation between the 
plantar flexors and extensors of the hips strength with the scores of D1; and also between 
the finger extensors and dorsiflexors of the ankles strength with the scores of D2. The 
strength values of the finger extensors, dorsiflexors, ankle inverters and eversion were 
significantly positive correlated with the score of D3; and the plantar flexors, dorsiflexors, 
eversion ankles, and hip extensors strength were significantly positive correlated with the 
total score of P-MFM. 
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Analyzing the correlations between the neck and trunk strength, with each dimension and 
the total score of P-MFM, we observed a significantly correlation between the neck and 
abdominal flexor with D1; between neck flexors with the D3; and between neck flexors and 
abdominal flexor with total score. 
The assessment of functional capacity and degree of muscle strength in patients with 
neuromuscular disease are essential aspects for their diagnosis and follow-up. Assistance in 
clinical decisions, treatment, prevention of any complications (like respiratory failure or 
retractions), indication of the type and intensity of exercise are important aspects to be 
considered (57,58).  
The MD-1 shows a pattern of muscle weakness primarily affecting the facial muscles, neck 
flexors, and dorsiflexors of fingers. The proximal muscles may not show deficits or mild 
clinical signs (2,59,60). Lindeman et al. (59,61) showed that in MD-1 there is a great variability 
in degrees of strength in the affected muscle groups (62.63). The symmetric and progressive 
muscular weakness involves proximal muscles (64). The deficit predominantly distal and axial 
deficits, as well as the later weakness proximal segments was also demonstrated in studies by 
Whittaker et al. (60), Lindeman and Drukker (65) and Lindeman et al. (66). Similar topography 
of motor impairment was observed in this study, in patients with MD-1. 
The strength graduated in 4 on the MRC scale, defined as the ability of active muscle 
contraction against moderate resistance, was correlated with a negative impact on the ability 
to perform functions like running, climbing stairs and walking (55,59,67,68,69,70,71,72). 
In this study, we found a great variability in the degree of muscle strength with greater 
involvement in distal segments of the lower limbs, and motor skills assessed by the P-MFM 
and a greater activity limitation in the standing position and transfers. The positive 
correlations obtained between muscle groups and the dimensions of P-MFM were restricted, 
noting that the most significant one occurred between the groups with lower degree of 
strength of the distal segment (hand and foot) and D3. 
According to Whittaker et al. (60) the weakness of flexors and extensors of fingers and wrist 
is the major cause of disability in DM-1. This early involvement of distal muscles allowed 
the correlation of these groups, especially with the D3. The proximal and axial body 
segments act as posture stabilizer factors to provide a stable basis for the distal movement 
(73). Considering that during the measurement of the scale items the subjects had trunk and 
limbs supported, they did not need an effective action from the muscles of the trunk and 
proximal limbs. So, it was possible to correlate specifically the strength of distal muscles 
with their respective activities. 
Poor limitations in proximal muscle groups (extensors of the hip and shoulder) were 
observed in few activities (Dimensions 1 and 2) limiting other activities (60,65,66) in late 
stage of this disease. 
The proximal muscular deficit can influence the performance function (64, 74, 75, 76.77, 78). 
According to Galassi et al. (79) and Linssen et al. (55) even when the weakness is 
predominantly in the distal limb segments, there is a bilateral proximal atrophy area in the 
computer tomography scans from patients with muscular dystrophy, also demonstrating 
the involvement of bilateral and proximal muscles, even when there is a clear manifestation 
of symptoms.  
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Lindeman et al. (59,61,76)and Aldehag et al. (80) correlated a specific muscle with a 
particular activity (like the quadriceps strength and standing up from a chair) in patients 
with DM-1, and found a positive correlation between strength and function. However 
Dawes et al. (81) found no correlation between muscle strength and function, when these 
activities were more complex. 
Besides strength, other variables may be influencing the individual's functional ability, such 
as age (82), gender and weight (83). In our cases these variables were not considered because 
they were not included in the objectives. 
So, it is important to analyze a large number of myotonic dystrophy patients to observe any 
correlation between strength and motor function. 
5. Final considerations 
The use of MFM proved to be an interesting tool in the study of the congenital myopathies 
as CFTD; although we were limited by time and sample size. The correlation of severe 
myopathy and mMRI data for smaller scale scores P-MFM, enables the use of a non-invasive 
diagnostic tool to study the course of myopathy diseases. They also indicate that both 
methods could be used in to analyse the results of pharmacological interventions and 
rehabilitation in these diseases. 
The P-MFM has a high reliability and validity to be used as a tool for clinical diagnosis and 
monitoring of neuromuscular diseases, allowing the inclusion of Brazilian patients in 
international clinical trials. Thus, we can mention that: 
1. The positive correlations between the BI, Vignos scale and P-MFM allowed the 
validation of P-MFM in Brazil. 
2. The application of P-MFM could demonstrate the progressive dysfunction in two of the 
three members of a family with CFTD. The muscle magnetic resonance showed that the 
more severe the motor function, the worse were the changes in the image worst severe 
functional motor, the worst change images. 
3. The application of P-MFM in MD-1 showed the predominance of distal myopathy, 
expressed by the lower scores of muscle strength correlating positively with the scores 
mainly in D3. 
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